Boardwalk Pipeline Partners, LP (BWP) Forms $13.20 Double Bottom; Catalina Lighting (CALA) Has 1.22 Sentiment

Calithera Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule drugs directed against tumor metabolism and tumor immunology targets for the treatment of cancer in the United States. The company has market cap of $294.46 million. The Company’s lead product candidate is CB-839, an inhibitor of glutaminase, which is in Phase Ib/2 clinical trials for the treatment of solid tumors. It currently has negative earnings. The firm has a license agreement with Mars, Inc. to develop and commercialize SymbioscienceÂ’s portfolio of arginase inhibitors for use in human healthcare; and license and research agreement with High Point Pharmaceuticals, LLC and TransTech Pharma LLC to develop and commercialize hexokinase II inhibitors.

Boardwalk Pipeline Partners, LP (BWP) formed double bottom with $12.14 target or 8.00% below today’s $13.20 share price. Boardwalk Pipeline Partners, LP (BWP) has $3.30 billion valuation. The stock decreased 0.23% or $0.03 during the last trading session, reaching $13.2. About 1.11 million shares traded. Boardwalk Pipeline Partners, LP (NYSE:BWP) has risen 11.68% since January 29, 2017 and is uptrending. It has underperformed by 5.02% the S&P500.

Atika Capital Management Llc holds 1.06% of its portfolio in Calithera Biosciences, Inc. for 234,603 shares. Ascend Capital Llc owns 658,195 shares or 0.39% of their US portfolio. Moreover, Viking Global Investors Lp has 0.27% invested in the company for 2.62 million shares. The Massachusetts-based Adage Capital Partners Gp L.L.C. has invested 0.13% in the stock. Franklin Street Advisors Inc Nc, a North Carolina-based fund reported 35,580 shares.

Analysts await Calithera Biosciences, Inc. (NASDAQ:CALA) to report earnings on March, 15. They expect $-0.24 EPS, up 46.67% or $0.21 from last year’s $-0.45 per share. After $-0.17 actual EPS reported by Calithera Biosciences, Inc. for the previous quarter, Wall Street now forecasts 41.18% negative EPS growth.

Ratings analysis reveals 50% of Calithera Biosciences’s analysts are positive. Out of 2 Wall Street analysts rating Calithera Biosciences, 1 give it “Buy”, 1 “Sell” rating, while 0 recommend “Hold”. CALA was included in 2 notes of analysts from October 25, 2016. The firm has “Buy” rating by H.C. Wainwright given on Thursday, January 5. The rating was initiated by Citigroup with “Sell” on Tuesday, October 25.

The stock decreased 1.78% or $0.15 during the last trading session, reaching $8.3. About 331,101 shares traded. Calithera Biosciences, Inc. (CALA) has risen 278.82% since January 29, 2017 and is uptrending. It has outperformed by 262.12% the S&P500.

Among 9 analysts covering Boardwalk Pipeline Partners (NYSE:BWP), 3 have Buy rating, 1 Sell and 5 Hold. Therefore 33% are positive. Boardwalk Pipeline Partners has $24 highest and $15.0 lowest target. $17.13’s average target is 29.77% above currents $13.2 stock price. Boardwalk Pipeline Partners had 19 analyst reports since August 13, 2015 according to SRatingsIntel. As per Tuesday, February 9, the company rating was maintained by Credit Suisse. The firm has “Overweight” rating given on Friday, May 27 by JP Morgan. RBC Capital Markets maintained Boardwalk Pipeline Partners, LP (NYSE:BWP) on Monday, October 9 with “Hold” rating. As per Friday, November 17, the company rating was initiated by Goldman Sachs. The firm has “Buy” rating given on Thursday, November 2 by Citigroup. As per Thursday, July 21, the company rating was downgraded by Ladenburg Thalmann. The rating was upgraded by Barclays Capital to “Equal-Weight” on Wednesday, January 17. The firm earned “Sector Perform” rating on Tuesday, August 1 by RBC Capital Markets. The company was maintained on Tuesday, February 7 by RBC Capital Markets. The firm earned “Hold” rating on Tuesday, January 16 by RBC Capital Markets.